Quantcast
Home > Quotes > BDSI
x
BDSI

BioDelivery Sciences International, Inc. Common Stock (BDSI) Quote & Summary Data

$3.64
*  
0.03
0.82%
Get BDSI Alerts
*Delayed - data as of Oct. 19, 2018  -  Find a broker to begin trading BDSI now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
4.501
Today's High / Low
$ 3.77 / $ 3.58
Share Volume
296,089
50 Day Avg. Daily Volume
557,275
Previous Close
$ 3.67
52 Week High / Low
$ 3.90 / $ 1.70
Market Cap
216,795,397
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.6

Intraday Chart

Shares Traded

Share Volume:
296,089
50 Day Avg. Daily Volume:
557,275

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -0.84

Trading Range

The current last sale of $3.64 is 114.12% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 3.77 $ 3.90
 Low: $ 3.58 $ 1.70

Company Description (as filed with the SEC)

We are a specialty pharmaceutical company with a focus in the areas of pain management and addiction medicine. We have built a portfolio of products utilizing our novel and proprietary BioErodible MucoAdhesive (or BEMA┬«) drug delivery technology, a small, erodible polymer film for application to the buccal mucosa (the lining inside the cheek), which we currently commercialize in the U.S. utilizing our own sales force while working in partnership with third parties to commercialize our products outside the U.S. We were incorporated in the State of Indiana in 1997 and were reincorporated as a Delaware corporation in 2002. BELBUCA┬«(buprenorphine) buccal film incorporates buprenorphine in our BEMA technology and was approved by the U.S. Food and Drug Administration ("FDA") on October 26, 2015, for the management of pain severe enough to require daily, around the clock, long-term opioid treatment for which alternative treatment options are inadequate.  ... More ...  


Risk Grade

Where does BDSI fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 3.68
Open Date:
Oct. 19, 2018
Close Price:
$ 3.64
Close Date:
Oct. 19, 2018

Consensus Recommendation

Analyst Info